RYTM
HealthcareRhythm Pharmaceuticals, Inc.
$101.86
$-3.15 (-3.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Rhythm Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $6.80B and over 283 employees. The company's financial health reveals significant losses as indicated by its net income (TTM) of -$197,711,008 and EBITDA of -$184,759,008. Additionally, Rhythm Pharmaceuticals has reported negative returns on equity (-85.8%) and assets (-26.7%), which contribute to its unprofitable status. The company's balance sheet shows a debt-to-equity ratio of 38.25 and $113.10M in debt, while it holds $416.05M in cash. The valuation of Rhythm Pharmaceuticals is characterized by negative earnings per share (P/E Ratio TTM: N/A) and a forward P/E of -38.93. The company's revenue growth rate is 54.3% year-over-year, but its earnings growth rate is not available. Notably, the company does not pay dividends to shareholders, as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $6.80B
- P/E Ratio
- N/A
- 52-Week High
- $122.20
- 52-Week Low
- $45.91
- Avg Volume
- 753.97K
- Beta
- 2.01
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 283